Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.
Robinson MK, Alpaugh RK, Borghaei H
Naptumomab estafenatox: a new immunoconjugate
Expert Opinion on Biological Therapy (2010) 10:273-279.
Importance of the field: New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials. Areas covered in this review: This review examines the preclinical and the published clinical data with regards to naptumomab. What the reader will gain: This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of this agent. Take home message: Naptumomab has a unique mechanism of action and appears to be an active agent in the treatment of refractory solid tumors such as renal cell carcinoma.
Publication Date: 2010-02-01.
PMCID: not NIH funded
Last updated on Tuesday, September 04, 2018